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ABSTRACT
Biomarkers enable early diagnosis, guide molecu-
larly targeted therapy and monitor the activity and
therapeutic responses across a variety of diseases.
Despite intensified interest and research, however,
the overall rate of development of novel biomarkers
has been falling. Moreover, no solution is yet
available that efficiently retrieves and processes
biomarker information pertaining to infectious dis-
eases. Infectious Disease Biomarker Database
(IDBD) is one of the first efforts to build an easily
accessible and comprehensive literature-derived
database covering known infectious disease bio-
markers. IDBD is a community annotation database,
utilizing collaborative Web 2.0 features, providing a
convenient user interface to input and revise data
online. It allows users to link infectious diseases or
pathogens to protein, gene or carbohydrate
biomarkers through the use of search tools. It
supports various types of data searches and
application tools to analyze sequence and structure
features of potential and validated biomarkers.
Currently, IDBD integrates 611 biomarkers for 66
infectious diseases and 70 pathogens. It is publicly
accessible at http://biomarker.cdc.go.kr and http://
biomarker.korea.ac.kr.
INTRODUCTION
Infectious diseases remain among the leading causes of
death and disability worldwide. About 15 million (>25%)
of 57 million annual deaths are estimated to be related
directly to infectious diseases (1). Newly emerging
and re-emerging infectious diseases constitute an urgent
and ongoing threat to public health throughout the
world. The discovery of acquired immune deﬁciency
syndrome (AIDS) has led to renewed appreciation of the
consequences of the emergence of infectious diseases.
Severe acute respiratory syndrome (SARS) emerged in
southern China in 2002 and has had a profound impact on
public health (2). Inﬂuenza viruses possess evolutionary
agility and the capacity to jump between fowl, farm
animal and human species (3). Just as troubling are
chronic infections, which create persistent social and eco-
nomic havoc. Recent studies have shown that the burden
of morbidity and mortality associated with certain infect-
ious diseases falls primarily on infants and young children
(4), with long-term social and economic consequences.
Surveillance and early response to infectious diseases
depend on rapid clinical diagnosis and detection, which, if
in place, are able to ameliorate suﬀering and economic
loss. Biomarkers, molecules that can be sensitively
measured in the human body, are by deﬁnition potentially
diagnostic. The eﬃcacy of biomarkers to infectious
diseases lies in their capability to provide early detection,
establish highly speciﬁc diagnosis, determine accurate
prognosis, direct molecular-based therapy and monitor
disease progression (5). They are increasingly important in
both therapeutic and diagnostic processes, with high
potential to guide preventive interventions. Vast resources
have been devoted to identifying and developing biomark-
ers that can help determine the treatments for patients.
Furthermore, there is growing consensus that multiple
markers will be required for most diagnoses, while single
markers may serve in only selected cases. Despite
intensiﬁed interest and research, however, the rate of
development of novel biomarkers has been falling (6),
suggesting that a resource that leverages existing data is
overdue. At present the databases containing information
about biomarkers are focused predominantly on cancer:
early detection research network (7), gastric cancer
knowledgebase (8), integrated cancer biomarker informa-
tion system (9) and database for cancer, asthma and
autism for children’s study (10). Even here, although
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chronic infection causes cancer (11), no systematic eﬀort
has been described for integrating information from the
cancer biomarker and the infectious disease domains.
In order to advance our understanding of biomarkers
and the roles in early infection processes, we have
developed an integrated user-friendly relational database
that catalogs putative and validated biomarkers relates
them to infectious diseases processes. In addition, we have
added value by hosting various bioinformatics tools that
can be used to analyze and visualize the biomarker data.
This freely accessible resource will be a valuable research
tool and a contribution to improved public heath.
OVERVIEW OF THE DATABASE
Infectious Disease Biomarker Database (IDBD) intro-
duces a community annotation database of biomarkers,
with interfaces for users to directly edit their content and
to keep track of editing history, thus capturing community
knowledge and expertise. It was designed to collect, store
and display information about biomarkers, conjoined to
research tools for sequence and structural analyses of the
data. IDBD currently includes information on 611
biomarkers from 66 infectious diseases and 70 pathogens
(Table 1). Biomarkers were classiﬁed according to detec-
tion, diagnosis, pathogen typing and virulence factor for
clinical or epidemiological studies and application.
Validated biomarkers were regarded as representative
markers for experimental veriﬁcation such as detection
and diagnosis of infectious diseases in the reference and
specialized laboratories or in scientiﬁc literatures.
Potential biomarkers were deﬁned as those frequently
cited in the context of detection and diagnosis of infectious
disease in recently published research journals. The correct
assignment of biomarker subtypes and the evaluation of
potential or validated biomarkers critically depend on
expert group in infectious disease research ﬁelds. The
IDBD data are updated and modiﬁed on a regular basis
by a curation team, composed of researchers at the Center
for Infectious Diseases and the Center for Immunology
and Pathology in the Korea National Institute of Health
(KNIH) in Seoul. The content in IDBD is open and freely
accessible to the general public, and IDBD is a part of the
National Disease Biomarker Bank project, an integrated
framework for identifying, collecting, distributing and
managing of biomarkers, which is being developed
at KNIH.
DATABASE DESIGN AND CONTENTS
IDBD primarily consists of the three main tables: disease,
pathogen and biomarker arranged in one Oracle schema
(12). Infectious diseases are divided into 10 subgroups
according to the infection site and the unique features of
the pathogen or disease: gastrointestinal infection, respira-
tory infection, neurological infection, urogenital infection,
viral hepatitis, hemorrhagic fever, zoonosis, arbovirus
infection, antibiotics resistance and bioterrorism. In total,
10 disease subgroups contain 66 diseases (Table 1). Each
disease at IDBD is characterized by a number of attributes
such as general information, pathogen, infection, symp-
tom, diagnosis, treatment and prevention. Pathogens are
grouped into bacteria, virus, fungi and parasite, currently
comprising 70 pathogens of mostly bacteria and virus.
Each pathogen is characterized by general information,
disease, biomarker list and related infection. Validated
and potential biomarker entries are divided into three
categories of detection/diagnosis, pathogen typing and
virulence factor, and users can then access the data
according to these criteria (Figure 1A).
The database contains approximately 8–9 biomarkers
per pathogen (Table 1), comprising proteins, nucleic acids,
carbohydrates and small molecules. Each biomarker
contains a number of categories of information: general
information, detection, mechanism, pathogen link,
sequence information, NCBI link, secondary structure,
tertiary structure, PDB link and reference. Biological
functions or roles of biomarkers are also included, if
available. Sequences are obtained from databases of
protein and nucleic acid sequences of the National
Center for Biotechnology Information (NCBI) (13).
Information of secondary and tertiary structures is
obtained from PDBsum at the European Bioinformatics
Institute (EBI) (14) and Protein Data Bank (PDB) (15),
respectively.
DATA RETRIEVAL
Biomarker data can be retrieved eﬃciently through
establishment of entry portals for search functions.
Users can access biomarker records from the front page
by clicking Biomarker at the top menu, which then allows
browsing of biomarkers in alphabetical order (Figure 1B).
Two diﬀerent search options are provided: Simple Search
can query the complete database by selecting one or
all three groups of biomarkers (protein, nucleic acid
and carbohydrate). Only one small molecule, a catechol
siderophore, is currently deposited. Speciﬁc database
queries can be deﬁned using the Complex Search
feature (Figure 1C), where ﬁelds of interest (class of
pathogen, molecular type, pathogen name, biomarker
name and NCBI accession number) can be selected from
Table 1. Current number of biomarker entries in IDBD
Disease groups Disease Pathogen Biomarker
Gastrointestinal infection 14 14 107
Respiratory infection 16 18 154
Neurological infection 2 1 14
Urogenital infection
a 91 0 4 6
Viral hepatitis
a 55 1 0
Hemorrhagic fever 4 4 37
Zoonosis 7 6 87
Arbovirus infection 5 5 110
Antibiotics resistance
a 66 8 3
Bioterrorism 8 8 83
Total
b 66 70 611
aDiseases, pathogens and biomarkers without overlapping with
other groups.
bTotal number of diseases, pathogens and biomarkers without
overlapping.
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ﬁelds in the pull-down menus by clicking the Add or
Delete button and in turn combining by AND or OR
operators. Both Simple and Complex Search returns a
result list of distinct biomarkers that matches the search
criteria (Figure 1D). The listed entries of biomarkers are
linked to detailed information (general information,
detection, mechanism, etc.), which can be viewed by
clicking the name of each biomarker. The sequence
information in the displayed list can be retrieved in a
separate window (Figure 1E), as amino acid sequence in
single letter abbreviation (protein) or nucleotide sequence
in FASTA format (nucleic acids) of the selected
biomarkers.
The complete contents of IDBD as well as other Web
resources can be searched via its user-friendly interface.
Three diﬀerent search options are provided: Internal,
External and News Search (Figure 2A). Internal Search
can query via either title or content search which extracts
textual content stored in the IDBD database including
disease, pathogens and biomarkers (Figure 2B). In the
case of External Search, users can submit a single query to
the NCBI PubMed, NCBI Entrez sequence database,
PDB structure database and Centers for Disease Control
and Prevention (CDC) (Figure 2C). Details of published
articles, sequence and structural data or disease and
pathogen information can be viewed in abstract terms and
sorted with regard to the information items. More detailed
Figure 1. A screenshot of IDBD showing (A) the list of biomarkers at the page of pathogen, classiﬁed according to detection/diagnosis, pathogen
typing and virulence factor, and the biomarker subtype page, (B) the list of biomarkers in alphabetical order, with two search options: Simple Search
and Complex Search, (C) Complex Search page, (D) search results and (E) retrieved sequences viewed in a separate window.
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sorted search data. News Search provides accurate and
timely information on the outbreaks and sporadic cases of
any infectious diseases. Users can search current news or
archives by entering keywords from scientiﬁc resources
including BBC News, ScienceNow from Science magazine
and Yahoo! News. More detailed information can be
displayed by clicking on the title of news articles sorted
by date.
DATA ANALYSIS
On the biomarker list page, IDBD allows access to
sequence and structure analysis tools by clicking ‘Data
analysis new window’ on the left-hand navigation bar. The
user can select sequences of interest obtained from
biomarker search (Figure 1E), prepare an input data by
clicking ‘Sequence alignment’, and conduct multiple
sequence alignment by direct submission or upload a ﬁle
of the chosen sequences to CLUSTALW tool of EBI (16).
On the result page (Figure 3A), the alignment can then be
exported for phylogenetic tree construction. The sequence
analysis also includes standard BLAST services (blastn
and blastp) on external network connectivity (17),
pairwise distance and synonymous—non-synonymous
ratio analysis. In the case of structure analysis, users
may submit an amino acid sequence or multiple sequences
aligned to a set of methods for secondary (PSA) and
tertiary structure (Geno3d) prediction (18,19). The pre-
dicted tertiary structures can be modeled by using Jmol
either with a PDB ﬁle or PDB ID, if available (Figure 3B).
FUTURE DIRECTIONS
Pathogen-speciﬁc biomarkers can provide information
necessary for diagnosis, detection and treatment of
various infectious diseases. Recent concerns about bio-
terrorism and emerging infectious diseases have led to a
new focus on the development of biomarkers, and
molecular diagnostics are growing fast in infectious
diseases. Currently, there are 611 biomarkers in IDBD
among which 239 are validated ones. The content of
biomarkers in IDBD is expanding rapidly, and our goal is
to collect a complete dataset of validated or potential
biomarkers used in the detection of infectious diseases and
to generate a knowledgebase that would be a valuable tool
for users interested in the discovery of infectious disease
biomarkers. The main challenge in the future is to
keep IDBD up to date with the growing number of
biomarkers experimentally veriﬁed and published in peer
Figure 2. Search examples showing (A) three search options: Internal, External and News Search, (B) Internal Search results and (C) External Search
results.
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support for database curation in the near future. Toward
this goal, a network of biomarker expert groups at the
Center for Infectious Diseases and the Center for
Immunology and Pathology at KNIH and advisory
committee outside KNIH has been formed to coordinate
database management and validation of novel biomarkers.
Another challenge is to provide IDBD with regional
epidemiological trends of some infectious diseases.
Epidemiological surveillance is key to control and monitor
diseases such as cholera, shigellosis, typhoid fever,
paratyphoid fever, rabies, etc. Since information on
infectious agents is essential in preventing and controlling
the spread of infectious diseases, it is necessary to collect,
analyze and publish the relevant information on a regional
scale, to the beneﬁt of the researchers studying infectious
diseases as well as the public. New insights into innate
immunity initiated by host–pathogen interaction are
changing the way we think about pathogenesis of
infectious diseases. Diﬀerent approaches are employed
for the characterization of immune responses by evalua-
ting the epitopes recognized by antigen-speciﬁc receptors
of immune systems. We intend to construct additional
tools useful for molecular immunological and etiological
applications. IDBD will collect intrinsic epitope features,
seasonal patterns of sequences and epitope responses to
Figure 3. The sequence and structure analysis tools showing (A) analysis results using selected sequences of biomarker data: sequence alignment and
phylogenetic tree, and (B) predicted 3D structure of a biomarker viewed with Jmol.
Nucleic Acids Research, 2008,Vol. 36,Database issue D459T and B cells, and develop software for epitope analysis
and prediction.
USER MANAGEMENT
The IDBD management system allows users to access the
biomarker database without registration. However, user
registration is required for adding and editing database
contents, and user support can be obtained by e-mailing
graduate@korea.ac.kr. Readers are encouraged to contact
us if they wish to provide new data for inclusion in IDBD,
assist with curation or have any suggestions for
improvements.
IMPLEMENTATION
IDBD was developed as a relational database using Oracle
10g applications (12) on the Windows operating system.
Two open source softwares, the Apache HTTP Server and
Apache Tomcat, were used as HTTP server and servlet
container for Web service, respectively. Perl scripts were
used to provide common gateway interface for sequence
alignment using ClustalW, and Java applet was used to
link Jmol for displaying 3D models. IDBD can be publicly
accessed from any Web browser at http://biomarker.cdc.
go.kr and http://biomarker.korea.ac.kr.
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